WO2007042289A3 - Nanobodies™ and polypeptides against egfr and igf-ir - Google Patents
Nanobodies™ and polypeptides against egfr and igf-ir Download PDFInfo
- Publication number
- WO2007042289A3 WO2007042289A3 PCT/EP2006/009840 EP2006009840W WO2007042289A3 WO 2007042289 A3 WO2007042289 A3 WO 2007042289A3 EP 2006009840 W EP2006009840 W EP 2006009840W WO 2007042289 A3 WO2007042289 A3 WO 2007042289A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanobodies
- polypeptides
- igf
- nucleic acids
- host cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06792421A EP1934259A2 (en) | 2005-10-11 | 2006-10-11 | Nanobodies and polypeptides against egfr and igf-ir |
CA002624781A CA2624781A1 (en) | 2005-10-11 | 2006-10-11 | Nanobodies tm and polypeptides against egfr and igf-ir |
US12/083,406 US20090252681A1 (en) | 2005-10-11 | 2006-10-11 | Nanobodies and Polypeptides Against EGFR and IGF-IR |
JP2008534933A JP2009511032A (en) | 2005-10-11 | 2006-10-11 | Nanobodies and polypeptides for EGFR and IGF-IR |
AU2006301426A AU2006301426A1 (en) | 2005-10-11 | 2006-10-11 | NanobodiesTM and polypeptides against EGFR and IGF-IR |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72593905P | 2005-10-11 | 2005-10-11 | |
US60/725,939 | 2005-10-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007042289A2 WO2007042289A2 (en) | 2007-04-19 |
WO2007042289A3 true WO2007042289A3 (en) | 2007-10-04 |
Family
ID=37837037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/009840 WO2007042289A2 (en) | 2005-10-11 | 2006-10-11 | Nanobodies™ and polypeptides against egfr and igf-ir |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1934259A2 (en) |
JP (1) | JP2009511032A (en) |
CN (1) | CN101321784A (en) |
AU (1) | AU2006301426A1 (en) |
CA (1) | CA2624781A1 (en) |
WO (1) | WO2007042289A2 (en) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
CA2588106A1 (en) * | 2007-05-18 | 2008-11-18 | Nrc - Institute For Biological Sciences | Single-domain antibodies and heavy chain antibody against egfr and uses thereof |
CN104231082B (en) | 2007-05-24 | 2018-12-21 | 埃博灵克斯股份有限公司 | The amino acid sequence for RANK-L for treating bone disease and illness and the polypeptide including it |
WO2008142165A1 (en) * | 2007-05-24 | 2008-11-27 | Ablynx N.V. | Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors |
EP2650311A3 (en) * | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
EP2274331B1 (en) | 2008-05-02 | 2013-11-06 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
JP6034023B2 (en) | 2008-05-16 | 2016-11-30 | アブリンクス エン.ヴェー. | Amino acid sequences directed to CXCR4 and other GPCRs and compounds containing the same |
US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
EP2143735A1 (en) * | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
GB0814960D0 (en) * | 2008-08-15 | 2008-09-24 | Ge Healthcare As | Method for detecting dysplasia |
WO2010070145A2 (en) | 2008-12-19 | 2010-06-24 | Ablynx N.V. | Method for generation of immunoglobulin sequences |
WO2011026948A1 (en) | 2009-09-03 | 2011-03-10 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
ES2572728T3 (en) * | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Bispecific anti-HER antibodies |
WO2010112194A1 (en) * | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
NZ595461A (en) * | 2009-04-10 | 2013-01-25 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
EP2417162A2 (en) | 2009-04-10 | 2012-02-15 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
US9139825B2 (en) | 2009-10-30 | 2015-09-22 | Novartis Ag | Universal fibronectin type III bottom-side binding domain libraries |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
BR112012013205B1 (en) * | 2009-12-18 | 2020-11-03 | Novozymes, Inc. | mutant of a parental strain of trichoderma reesei, and methods to produce a polypeptide of interest and to obtain a mutant of a parental strain of trichoderma |
WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
CN102781959A (en) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
US8937164B2 (en) | 2010-03-26 | 2015-01-20 | Ablynx N.V. | Biological materials related to CXCR7 |
RU2012149227A (en) * | 2010-05-20 | 2014-06-27 | Аблинкс Нв | BIOLOGICAL MATERIALS RELATING TO HER3 |
GB201014715D0 (en) * | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
CN102153650B (en) * | 2011-01-27 | 2012-07-04 | 中国人民解放军军事医学科学院生物工程研究所 | Anti-EGFR (epidemic growth factor receptor) humanized antibody L2-H3 and coding gene and application thereof |
JP6181040B2 (en) | 2011-03-28 | 2017-08-16 | アブリンクス エン.ヴェー. | Bispecific anti-CXCR7 immunoglobulin single variable domain |
UA117218C2 (en) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
AU2012264809B2 (en) | 2011-05-27 | 2017-05-04 | Ablynx Nv | Inhibition of bone resorption with RANKL binding peptides |
CN102321175B (en) * | 2011-09-21 | 2013-08-07 | 天津胜发生物技术有限公司 | Nano-antibody or polypeptide aiming at breast cancer Her2/new |
EP3311837A1 (en) | 2011-09-23 | 2018-04-25 | Ablynx NV | Prolonged inhibition of interleukin-6 mediated signaling |
EP2747783B1 (en) | 2011-09-30 | 2017-06-14 | Ablynx N.V. | Biological materials related to c-met |
TW201843172A (en) * | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | Anti-egfr antibodies and uses thereof |
JP6025127B2 (en) | 2012-07-13 | 2016-11-16 | 学校法人帝京平成大学 | Antitumor agent, tumor detection marker and oral vaccine |
AU2013372026B2 (en) | 2013-01-03 | 2018-11-08 | Merck Patent Gmbh | Method for producing secretable antibodies by expression in saccharomyces cerevisiae |
AU2014326674B2 (en) * | 2013-09-26 | 2020-03-12 | Ablynx Nv | Bispecific nanobodies |
US10106614B2 (en) * | 2014-03-06 | 2018-10-23 | National Research Council Of Canada | Insulin-like growth factor 1 receptor-specific antibodies and uses thereof |
CA2942154C (en) * | 2014-03-06 | 2023-06-27 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
AU2014385801B2 (en) * | 2014-03-06 | 2020-11-12 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
BR112016021383A2 (en) | 2014-03-24 | 2017-10-03 | Genentech Inc | METHOD TO IDENTIFY A PATIENT WITH CANCER WHO IS LIKE OR LESS LIKELY TO RESPOND TO TREATMENT WITH A CMET ANTAGONIST, METHOD TO IDENTIFY A PATIENT WITH PREVIOUSLY TREATED CANCER, METHOD TO DETERMINE THE EXPRESSION OF THE HGF BIOMARKER, ANTI-C-MET ANTAGONIST AND ITS USE, DIAGNOSTIC KIT AND ITS PREPARATION METHOD |
CA2963712A1 (en) | 2014-10-21 | 2016-04-28 | Ablynx Nv | Treatment of il-6r related diseases |
KR101679245B1 (en) | 2014-12-09 | 2016-11-25 | 전남대학교산학협력단 | A composition for diagnosing or imaging cancer targeting epidermal growth factor receptor |
JP6862343B2 (en) * | 2014-12-19 | 2021-04-21 | アブリンクス エン.ヴェー. | Cysteine-bonded nanobody dimer |
CN106854244B (en) * | 2015-12-09 | 2020-05-22 | 南京英瀚斯生物科技有限公司 | Nano antibody aiming at HER3 and clinical application thereof |
WO2018052503A1 (en) * | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
CN106492216A (en) * | 2016-10-28 | 2017-03-15 | 山西纳安生物科技有限公司 | Nano antibody drug-delivery preparation system and preparation method and application through exocuticle in incidence |
WO2019016237A1 (en) * | 2017-07-19 | 2019-01-24 | Vib Vzw | Serum albumin binding agents |
WO2019014891A1 (en) * | 2017-07-20 | 2019-01-24 | 深圳普瑞金生物药业有限公司 | Egfr single-domain antibody cart for treating tumor and application thereof |
PE20212205A1 (en) * | 2017-09-08 | 2021-11-18 | Maverick Therapeutics Inc | RESTRICTED CONDITIONALLY ACTIVATED BINDING PROTEINS |
EP3725806A4 (en) * | 2017-12-14 | 2022-03-30 | ABL Bio Inc. | Bispecific antibody to a-syn/igf1r and use thereof |
GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
CN112521504B (en) * | 2018-09-27 | 2022-08-16 | 暨南大学 | Anti-human EGFR nano antibody and application thereof |
JP2022524338A (en) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | Restrained and conditionally activated binding protein |
WO2021006819A1 (en) * | 2019-07-10 | 2021-01-14 | Nanyang Technological University | Epidermal growth factor receptor (egfr) ligands |
CN111171151B (en) * | 2019-12-26 | 2021-09-14 | 佛山汉腾生物科技有限公司 | anti-EGFR (epidermal growth factor receptor) nano antibody and application thereof |
CN112375135B (en) * | 2020-07-06 | 2022-12-23 | 上海大学 | Artificial epidermal growth factor, designed polypeptide and application thereof |
EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
CN112646035B (en) * | 2020-12-25 | 2022-06-24 | 暨南大学 | Affinity maturation binding protein of EGFR (epidermal growth factor receptor) and application |
CN112646034B (en) * | 2020-12-25 | 2022-06-24 | 暨南大学 | Affinity maturation binding protein of EGFR (epidermal growth factor receptor) and application thereof |
WO2023288267A1 (en) | 2021-07-14 | 2023-01-19 | 2Seventy Bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
WO2023016828A2 (en) | 2021-07-30 | 2023-02-16 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
CA3232216A1 (en) * | 2021-10-18 | 2023-04-27 | Tavotek Biotherapeutics (Hong Kong) Limited | Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof |
WO2023143484A1 (en) * | 2022-01-29 | 2023-08-03 | 明慧医药(杭州)有限公司 | Antigen-binding protein and use thereof |
CN114621349B (en) * | 2022-02-09 | 2023-12-01 | 青岛大学附属医院 | Targeting PD-L1/HSA/CCL5 trispecific nano-antibody, derivative thereof and application thereof |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030165502A1 (en) * | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
WO2005016970A2 (en) * | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
WO2005044858A1 (en) * | 2003-11-07 | 2005-05-19 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
-
2006
- 2006-10-11 JP JP2008534933A patent/JP2009511032A/en not_active Withdrawn
- 2006-10-11 CA CA002624781A patent/CA2624781A1/en not_active Abandoned
- 2006-10-11 WO PCT/EP2006/009840 patent/WO2007042289A2/en active Application Filing
- 2006-10-11 EP EP06792421A patent/EP1934259A2/en not_active Withdrawn
- 2006-10-11 AU AU2006301426A patent/AU2006301426A1/en not_active Abandoned
- 2006-10-11 CN CNA2006800449688A patent/CN101321784A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030165502A1 (en) * | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
WO2005016970A2 (en) * | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
WO2005044858A1 (en) * | 2003-11-07 | 2005-05-19 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
Non-Patent Citations (3)
Title |
---|
ELS CONRATH K ET AL: "Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 10, 9 March 2001 (2001-03-09), pages 7346 - 7350, XP002248402, ISSN: 0021-9258 * |
LU D ET AL: "Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 4, 23 January 2004 (2004-01-23), pages 2856 - 2865, XP002316541, ISSN: 0021-9258 * |
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 79, March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
CA2624781A1 (en) | 2007-04-19 |
CN101321784A (en) | 2008-12-10 |
EP1934259A2 (en) | 2008-06-25 |
AU2006301426A1 (en) | 2007-04-19 |
JP2009511032A (en) | 2009-03-19 |
WO2007042289A2 (en) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007042289A3 (en) | Nanobodies™ and polypeptides against egfr and igf-ir | |
IL250946B (en) | Nanobodies tm against tumor necrosis factor-alpha | |
WO2009068627A3 (en) | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same | |
WO2008077945A3 (en) | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies | |
WO2008066752A3 (en) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir | |
WO2006122825A3 (en) | Single domain vhh antibodies against von willebrand factor | |
WO2008142164A3 (en) | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders | |
WO2008074867A3 (en) | Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use | |
WO2010120514A3 (en) | Antigen-binding proteins comprising recombinant protein scaffolds | |
WO2006119987A3 (en) | Recombinant n-glycosylated proteins from procaryotic cells | |
WO2007104529A3 (en) | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
WO2008074839A3 (en) | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders | |
WO2008025516A3 (en) | Tnf superfamily fusion proteins | |
WO2010051274A3 (en) | Fibronectin type iii domain based scaffold compositions, methods and uses | |
WO2005121331A3 (en) | Truncated galnact2 polypeptides and nucleic acids | |
WO2008005470A3 (en) | Polypeptides that bind membrane proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680044968.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006792421 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006301426 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2624781 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008534933 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12083406 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3070/DELNP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2006301426 Country of ref document: AU Date of ref document: 20061011 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006301426 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006792421 Country of ref document: EP |